Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells (Q44960581)

7 December 2017

title

Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells (English)

1 reference

7 December 2017

A Aartsma-Rus

1 reference

7 December 2017

W E Kaman

1 reference

7 December 2017

M Bremmer-Bout

1 reference

7 December 2017

A A M Janson

1 reference

7 December 2017

J T den Dunnen

1 reference

7 December 2017

G-J B van Ommen

1 reference

7 December 2017

J C T van Deutekom

1 reference

7 December 2017

publication date

1 September 2004

1 reference

7 December 2017

1 reference

7 December 2017

1 reference

7 December 2017

1 reference

7 December 2017

page(s)

1391-1398

1 reference

Novel antisense and peptide nucleic acid strategies for controlling gene expression

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Correction of disease-associated exon skipping by synthetic exon-specific activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Morphant technology in model developmental systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Morpholino antisense oligomers: the case for an RNase H-independent structural type

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Achieving efficient delivery of morpholino oligos in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Effective targeted gene 'knockdown' in zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Systemically delivered antisense oligomers upregulate gene expression in mouse tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

DNA analogues: from supramolecular principles to biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Antisense properties of peptide nucleic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Additive antisense effects of different PNAs on the in vitro translation of the PML/RARalpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

7 January 2021

Dystrophin-associated protein abnormalities in dystrophin-deficient muscle fibers from symptomatic and asymptomatic Duchenne/Becker muscular dystrophy carriers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

7 January 2021

Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

7 January 2021

Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302313

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302313

1 reference

7 December 2017

1 reference